PF-Atlas › Clinical Trials › NCT03601637

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

LUM · Phase 3

Registry ID

NCT03601637

Phase

Phase 3

Status

Completed

Drug / intervention

LUM

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2018-09-07

Enrollment

Locations

About this trial

This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).

View NCT03601637 on ClinicalTrials.gov →

Explore related

All LUM trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03601637 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.